Dermatitis News

Once-daily roflumilast foam 0.3% demonstrated safety and efficacy in the treatment of erythema, scaling and itching caused by seborrheic dermatitis, according to a phase 2a study.

New data from a phase 2 study evaluating the short-term clinical benefits of Opzelura cream 1.5% showed a reduction in itch among adults with mild to moderate atopic dermatitis, Incyte announced in a press release.

Children born by caesarean section had an increased risk for developing atopic dermatitis before age 5 years compared with children born by vaginal delivery, according to a study published in Pediatric Allergy and Immunology.

Gusacitinib significantly outperformed placebo, showing a tolerable safety profile and a rapid improvement in the treatment of patients with chronic hand eczema, according to a phase 2 study.

Alphyn Biologics reported positive results for topical AB-101a in a phase 2a clinical trial in pediatric patients with mild to moderate atopic dermatitis.

A bacterial decolonization-based regimen safely and effectively prevented development of severe acute radiation dermatitis among adults receiving radiation therapy, results of a randomized phase 2/phase 3 trial showed.

Tralokinumab at doses of 150 mg or 300 mg was associated with improvements over placebo in a number of efficacy outcomes at 16 weeks and 52 weeks in adolescents with moderate to severe atopic dermatitis, according to a study.

People with allergic diseases had an increased risk for cataract surgery, an association more evident in men aged younger than 50 years and in those with both atopic dermatitis and allergic rhinitis, according to data in Scientific Reports.

Multiple phase 3 studies found that lebrikizumab improved face and hand dermatitis in a majority of patients at 16 weeks and maintained a stable response through 52 weeks, Eli Lilly and Company announced in a press release.

Evelo Biosciences has announced that it will cease further development of EDP1815 for atopic dermatitis following its phase 2 study results that showed the primary endpoint was not met, according to a company press release.